AN OPEN-LABEL, SINGLE-ARM 4-YEAR STUDY TO EVALUATE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB TREATMENT IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS
Latest Information Update: 19 Mar 2025
At a glance
- Drugs Ocrelizumab (Primary)
- Indications Multiple sclerosis
- Focus Registrational; Therapeutic Use
- Acronyms CONSONANCE
- Sponsors Roche
Most Recent Events
- 13 Sep 2023 This trial has been completed in Ireland, according to European Clinical Trials Database record.
- 12 Aug 2023 This trial has been completed in Hungary.
- 26 Oct 2022 Status changed from recruiting to active, no longer recruiting.